- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
35 result(s) found for: Chimeric Protein.
Displaying page 1 of 2.
EudraCT Number: 2014-001736-11 | Sponsor Protocol Number: CYD33 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-005358-27 | Sponsor Protocol Number: ASMAB1 | Start Date*: 2006-07-12 |
Sponsor Name:University Hospital of North Staffordshire | ||
Full Title: Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance imaging study | ||
Medical condition: Ankylosing spondylitis (AS) is an inflammatory condition primarily affecting the spine. The disease may remain symptomatic and progressive life-long. It is part of the family of spondyloarthropat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003829-29 | Sponsor Protocol Number: EMR200637-002 | Start Date*: 2014-10-27 | |||||||||||
Sponsor Name:Symphogen A/S | |||||||||||||
Full Title: Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Color... | |||||||||||||
Medical condition: Metastatic colorectal cancer with Acquired Resistance to Anti-EGFR Monoclonal Antibodies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) BE (Completed) AT (Completed) HU (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005777-30 | Sponsor Protocol Number: 26866138-LYM-3001 | Start Date*: 2006-03-31 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non Hodgkin's Lymphoma | |||||||||||||
Medical condition: Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non Hodgkin's Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) SK (Completed) ES (Completed) DE (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001242-35 | Sponsor Protocol Number: 68284528MMY3004 | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) ES (Ongoing) HU (Ongoing) AT (Trial now transitioned) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001742-13 | Sponsor Protocol Number: 06_RADIO_56 | Start Date*: 2006-10-04 |
Sponsor Name:Christie Hospital NHS Trust | ||
Full Title: Locally Advanced Pancreatic Cancer: Phase II study of cetuximab and 3-D conformal image-guided radiotherapy (PACER Study) | ||
Medical condition: Adenocarcinoma of the pancreas which is locally advanced/inoperable | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-007170-30 | Sponsor Protocol Number: TUD-Psslan-031 | Start Date*: 2008-06-03 |
Sponsor Name:Technical University of Dresden, faculty of medicine | ||
Full Title: Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten Investigation of phenotype and f... | ||
Medical condition: Psoriasis vulgaris | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2018-001023-38 | Sponsor Protocol Number: bb2121-MM-003 | Start Date*: 2019-05-13 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (... | ||||||||||||||||||
Medical condition: Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of com... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) SE (Completed) DE (Ongoing) BE (Ongoing) NO (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001904-36 | Sponsor Protocol Number: C0328T06 | Start Date*: 2006-09-07 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade® versus Velcade alone in Subjects with Relapsed or Re... | |||||||||||||
Medical condition: relapsed or refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) FR (Completed) GB (Completed) CZ (Completed) PT (Completed) DE (Completed) GR (Completed) BG (Completed) SK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000922-59 | Sponsor Protocol Number: IM101-043 | Start Date*: 2004-12-01 |
Sponsor Name:Bristol Myers Squibb International Corporation | ||
Full Title: A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination with Methotrexate in Controlling Disease Activity in Subjects wit... | ||
Medical condition: Rheumatoid Arthrithis, Nos | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) CZ (Completed) ES (Completed) | ||
Trial results: Removed from public view |
EudraCT Number: 2019-001413-16 | Sponsor Protocol Number: 68284528MMY3002 | Start Date*: 2020-05-15 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, ... | |||||||||||||
Medical condition: Relapsed and lenalidomide-refractory multiple myeloma (MM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) NL (Ongoing) PL (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001735-22 | Sponsor Protocol Number: CNTO328SMM2001 | Start Date*: 2011-09-28 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma | |||||||||||||
Medical condition: High-risk Smoldering Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) SE (Completed) FR (Completed) GR (Completed) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023562-51 | Sponsor Protocol Number: BT-CL-PGG-CRC1031 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:Biothera | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
Medical condition: Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000121-32 | Sponsor Protocol Number: 68284528MMY2001 | Start Date*: 2019-09-03 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002245-29 | Sponsor Protocol Number: BB2121-MM-001 | Start Date*: 2018-10-02 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma | ||||||||||||||||||
Medical condition: Relapsed and Refractory Multiple Myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017237-22 | Sponsor Protocol Number: CNTO328MMY3001 | Start Date*: 2011-01-31 | |||||||||||
Sponsor Name:Janssen Biologics B.V. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refra... | |||||||||||||
Medical condition: Subjects With Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) ES (Completed) CZ (Prematurely Ended) PT (Completed) NL (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004098-33 | Sponsor Protocol Number: 233AS101 | Start Date*: 2016-06-29 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide D... | ||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DK (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001379-18 | Sponsor Protocol Number: QEL-001-CLN-01 | Start Date*: 2023-04-25 | |||||||||||
Sponsor Name:Quell Therapeutics Limited | |||||||||||||
Full Title: A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg pa... | |||||||||||||
Medical condition: Prevention of liver transplant rejection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001897-26 | Sponsor Protocol Number: C0328T05 | Start Date*: 2006-09-07 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 2 Multicenter Study of CNTO 328 (Anti Interleukin 6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: relapsed or refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003436-13 | Sponsor Protocol Number: 105RC101 | Start Date*: 2016-05-24 | |||||||||||
Sponsor Name:TRACON Pharmaceuticals, Inc. | |||||||||||||
Full Title: A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA | |||||||||||||
Medical condition: ADVANCED OR METASTATIC RENAL CELL CARCINOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Prematurely Ended) PL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.